Paulina Rzasa

Paulina Rzasa

Auto-generated profile, based on publicly available information

Paulina Rzasa

Leicester Cancer Research Centre, University of Leicester, Leicester, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
PRPaulina Rzasa
Paulina Rzasa
SWSarah Whelan
Sarah Whelan
PFPooyeh Farahmand
Pooyeh Farahmand
HCHong Cai
Hong Cai
IGInna Guterman
Inna Guterman
ARAlessandro Rufini
Alessandro Rufini
BRAF mutations occur early in serrated colorectal cancers, but their long-term influence on tissue homeostasis is poorly characterized. We investigated the impact of short-term (3 days) and long-term (6 months) expression of BrafV600E in the intestinal tissue of an inducible mouse model. We show that BrafV600E perturbs the homeostasis of intestinal epithelial cells, with impaired differentiation of enterocytes emerging after prolonged expression of the oncogene. Moreover, BrafV600E leads to a persistent transcriptional reprogramming with enrichment of numerous gene signatures indicative of proliferation and tumorigenesis, and signatures suggestive of metabolic rewiring. We focused on the top-ranking cholesterol biosynthesis signature and confirmed its increased expression in human serrated lesions. Functionally, the cholesterol lowering drug atorvastatin prevents the establishment of intestinal crypt hyperplasia in BrafV600E-mutant mice. Overall, our work unveils the long-term impact of BrafV600E expression in intestinal tissue and suggests that colorectal cancers with mutations in BRAF might be prevented by statins.

4 January 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
PRPaulina Rzasa
Paulina Rzasa
ARAlessandro Rufini
Alessandro Rufini

6 March 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PFPooyeh Farahmand
Pooyeh Farahmand
PRPaulina Rzasa
Paulina Rzasa
CGCaleb Green
Caleb Green
FHFiona Hey
Fiona Hey
SGSusan Giblett
Susan Giblett
ARAlessandro Rufini
Alessandro Rufini
Valine to glutamate substitution at residue 600 of the BRAF oncogene ( V600E BRAF mutation) is prevalent in human colorectal cancers with a serrated histopathology and is thought to be a founder mutation. Using a conditional knock-in mouse model we have previously demonstrated that V600E Braf drives crypt hyperplasia in the short term as well as shortened survival linked to increased tumour burden in the long-term. These phenotypes are associated with induction of gene signatures for E2F targets, MYC signalling, G2/M transition, canonical Wnt signalling, and cholesterol biosynthesis. Although these gene signatures are reverted by MEK inhibition, there remains a lack of understanding of the signalling pathways involved, particularly the mechanism of crosstalk between the MAPK and Wnt pathways. Here, we have examined a role for phosphorylation of GSK3αβ isoforms at residues S21/S9. By introducing homozygous knock-in mutations for Gsk3αβ S9A/S21A onto the V600E Braf background, we unexpectedly show a marginal effect of these mutations on further increasing crypt proliferation. However, this impact is lost in the long-term as there are no significant differences in mouse survival, tumour burden or tumour grade. Consistently, the Gsk3αβ knock-in mutations do not change the transcriptional programme induced by V600E Braf , except for 3 genes ( Ephx4 , Eif2b3 Ppp1r13l ) whose expression is significantly altered, potentially contributing to the short-term increase in crypt hyperplasia. Overall, our data show that therapeutic strategies targeting GSK3αβ phosphorylation at serines 21/9 are not worthwhile options for V600E BRAF colorectal cancers.